Gilead’s injectable drug is a potential game changer in efforts to curb HIV infections, according to health experts who are calling on the pharmaceutical giant to clearly lay out plans for access to the product.
Data from Gilead’s Phase 3, PURPOSE 1 trial showed that lenacapavir, a twice-yearly injectable, is 100% efficacious in preventing HIV in women and adolescent girls.
There were zero cases of HIV infection among the 2,134 women who were given the drug. It was also “generally well-tolerated and no significant or new safety concerns were identified,” according to a news release.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
